Searchable abstracts of presentations at key conferences in endocrinology

ea0049ep235 | Bone & Osteoporosis | ECE2017

Bone histomorphometry and bone marrow adipocytes in premenopausal women with type 2 diabetes

Andrade Vicente , Borba Victoria , Chula Domingos , Barreto Fellype , Boguszewski Cesar , Moreira Carolina

Few studies have evaluated bone histomorphometry in type 2 diabetic patients (DM2) and none has established if the disease control plays a role on bone morphology and bone marrow adipocytes. The aim of this study is to present preliminary data on bone microstructure, bone formation rate and bone marrow adipocytes in premenopausal women with DM2 with different levels of glucose control. Bone biopsy, followed by tetracycline labelling, was obtained for analysis of static and dyn...

ea0063s26.3 | Impact of thyroid disease on... | ECE2019

Thyroid hormones in the cardiac physiopathology

Barreto-Chaves Maria Luiza

Our group studies the influence of different endocrine factors on cardiovascular function. Ang II is the main vasopeptide of Renin-Angiotensin System (RAS) and exerts its potent biological effects through AT1 and AT2 receptors. In heart, Ang II induces cardiomyocyte hypertrophy and fibroblast hyperplasia through TGF-β1 recruitment. On the other hand, cardiovascular system is very sensitive to the action of the Thyroid Hormones (THs). One major cardiovascular manifestation...

ea0041ep131 | Bone & Osteoporosis | ECE2016

Barrett’s esophagus and osteopenia: Report of a case

Athanassiou Panagiotis , Tzanavari Aikaterini , Spyridis Anestis , Kostopoulos Markos , Xanthakou Eleni , Kostoglou-Athanassiou Ifigenia

Introduction: Barrett’s esophagus is metaplasia in the cells of the lower end of the esophagus. It is characterized by the replacement of the normal stratified squamous epithelium lining of the esophagus by simple columnar epithelium with goblet cells. The disease is often related to gastroesophageal reflux and patients have pain necessitating chronic usage of proton pump inhibitors. Proton pump inhibitors have been associated with the development of low bone mineral dens...

ea0029p871 | Endocrine tumours and neoplasia | ICEECE2012

Leydig cell tumor of ovary: a rare case of virilization

Souto S. , Vieira-Baptista P. , Barreto F. , Carvalho-Braga D. , Carvalho D.

Introduction: Leydig cell tumors are a type of steroid cell tumor, account for 0.1% of all ovarian tumors. The clinical presentation is usually a hyperandrogenic state with signs of virilisation. The tumor has a benign behavior, with an excellent prognosis and reversion of symptoms after surgical treatment.Case report: Woman, 81 years-old, nulliparus, with clinic hyperandrogenism and vaginal bleeding during the last year. She had history of dementia synd...

ea0084ps2-08-75 | Thyroid Cancer BASIC | ETA2022

PD-L1 and MCL-1 markers and the relationship with prognostic characteristics of differentiated thyroid carcinoma

Engelbrecht Zantut Wittmann Denise , Siqueira Barreto Icleia , Carolina Laus Ana , Moreno Daniel , Moma Camila , Maia Frederico , Vera Montalli Assumpcao Ligia , Reis Rui

Objectives: MCL-1 and PD-L1 proteins are related to carcinogenesis mechanisms in differentiated thyroid carcinoma (DTC). Tumor antigens stimulate the expression of PD-1 in immune cells, which binds to PD-L1 of tumor cells, inducing immune escape from the tumor. MCL-1, an anti-apoptotic member of the BCL-2 family and has a high oncogenic potential. The relationship of these markers with prognosis in DTC remains unknown. We aim to evaluate the clinical utility of immunohistochem...

ea0084ps2-08-76 | Thyroid Cancer BASIC | ETA2022

Double mutation of the TERT promoter in extremely aggressive papillary thyroid carcinoma

Engelbrecht Zantut Wittmann Denise , Carolina Laus Ana , Moreno Daniel , Siqueira Barreto Icleia , Moma Camila , Maia Frederico , Etchebehere Elba , Vera Montalli Assumpcao Ligia , Reis Rui

Objectives: BRAFV600E mutation is present in 50% of aggressive papillary thyroid carcinoma(PTC). TERT promoter (pTERT) mutations (C228T, C250T) are related to cancer growth and reduced overall- and disease-free survivals in differentiated thyroid carcinomas(DTC). We report a patient with an extremely aggressive PTC presenting in the primary lesion two pTERT mutations (C228T and C250T), and absence of BRAFV600E.<p class="abstext"...

ea0085oc7.3 | Oral Communications 7 | BSPED2022

Hypogonadism and pubertal disorders in wolfram syndrome

Newell Laura , Cunningham Olivia , Williams Denise , Barrett Timothy , Dias Renuka

Background: Wolfram Syndrome (WS) is a rare autosomal recessive disorder characterised by early-onset diabetes and optic atrophy as well as a variable spectrum of other endocrine and neurological conditions. It is caused by mutations in the WFS1 gene. Previous reports have documented a variable prevalence of hypogonadism (6.3% of the international EURO-WABB registry, 34% of a German cohort); however the only UK cohort reported was of 10 males, 7 of whom had primary gonadal atr...

ea0084ps3-12-110 | Graves’ Disease 2 and Orbitopathy | ETA2022

Linear mixed model analysis of quality of life scores in patients with thyroid eye disease treated with teprotumumab from three 24-week clinical trials

Kahaly George , Qashqai Anahita , Barretto Naina , Vesel Claudia , Holt Robert

Objectives: Teprotumumab, an IGF1-receptor antagonist, has been shown in three clinical trials to markedly improve the clinical course of Thyroid Eye Disease (TED) or Graves’ Orbitopathy (GO) with significant improvements noted in inflammation, proptosis, and diplopia. Furthermore, compared to placebo moderate-to-large improvements were noted in the total, appearance (AP), and visual function (VF) as measured by EUGOGO GO quality of life (GO-QOL) scores after 24 weeks of ...

ea0066s3.3 | Diabetes Track 1: Symposium 3 | BSPED2019

Newer treatments for type 2 diabetes in children

Barrett Timothy

It is over 17 years since the randomised controlled trial of metformin showed efficacy in childhood type 2 diabetes. Since that time, despite much investment in paediatric investigation plans, very few interventional clinical trials have reported. This presentation reviews the evidence for childhood type 2 diabetes being different to adult type 2 diabetes. Childhood type 2 diabetes is a more aggressive disease; children have lower insulin sensitivity than adults; and complicat...